Search
deutetrabenazine; tetrabenazine D6 (Austedo)
Indications:
- treatment of Huntington's chorea (FDA-approved April 2017)
Contraindications:
- suicidal ideation
- hepatic impairment
- concurrent administration of: MAOI, reserpine, tetrabenazine
Dosage:
- start 6 mg PO QD
- max: 24 mg PO BID
- in poor CYP2D6 metabolizers 18 mg PO BID
- BID dosing >= 12 mg QD
- administer with food
- swallow tablets whole; do not chew, crush, or break
Tabs: 6 mg, 9 mg, 12 mg
Adverse effects:
- common (> 8%)
- somnolence, diarrhea, xerostomia, fatigue
Drug interactions:
- strong CYP2D6 inhibitors
- alcohol or sedative may increase somnolence, sedation
Mechanism of action:
- inhibits vesicular monoamine 2 transporter (VMAT2)
General
neurologic agent
heterocyclic compound, 3 rings
ether
amine
ketone
Database Correlations
PUBCHEM correlations
References
- Fiore K
FDA Okays First Tardive Dyskinesia Drug -
VMAT2 inhibitor diminished abnormal involuntary movements in
pivotal trial.
MedPage Today. April 11, 2017
https://www.medpagetoday.com/Neurology/GeneralNeurology/64513
- Brooks M
FDA Clears Deutetrabenazine (Austedo) for Huntington's Chorea.
Medscape - Apr 04, 2017
http://www.medscape.com/viewarticle/8781621
- Windle ML.
FDA New Drug and Biologic Approvals -- 2017 Year-in-Review
Medscape - Jan 11, 2018.
https://reference.medscape.com/viewarticle/890871
- U.S. Food and Drug Administration.
Novel Drug Approvals for 2017.
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm
- Huntington Study Group, Frank S, Testa CM, Stamler D et al
Effect of Deutetrabenazine on Chorea Among Patients With
Huntington Disease: A Randomized Clinical Trial.
JAMA. 2016 Jul 5;316(1):40-50.
PMID: 27380342 Free Article
- Highlights of Prescribing Information
Austedo (deutetrabenazine)
https://www.austedo.com/pi